Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

During the first quarter, the Global Women’s Leadership portfolio lagged global developed market equities overall in the ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...

Insmed shares rocketed on results for a pulmonary arterial hypertension drug that exceeded Wall Street expectations.

Gilead Sciences has announced that the U.S. Food and Drug Administration has placed a clinical hold on its HIV treatment ...

On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: ...

Gilead was putting the two drugs through their paces in a series of clinical trials, which were at various stages. The ones in the mid-to-late cycles were testing the pair against its currently ...

Shares of Gilead Sciences Inc. GILD shed 2.58% to $110.09 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.55% to 6,038.81 ...

Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ET. Company Participants. Daniel P. O'Day - Chairman & CEO. Confe ...

Analysts at Citi said that while the clinical hold impacts the targeted commercial launch of the GS-1720/GS-4182 regimen, previously expected around 2029/2030, they believe the setback is minor, as it ...

The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...